Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS8 | O00214 | 7/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | MGAM | O43451 | 4/20 | 0.36 |
| ▸ | SI | P14410 | 4/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15267647 | 1.00 | LGALS8 (0.43) | LGALS8ALDH1A1HIF1AMGAMSI | |
| SCHEMBL20582504 | 0.92 | LGALS8 (0.41) | LGALS8ALDH1A1HIF1AMGAMSI | |
| SCHEMBL15267318 | 0.88 | LGALS8 (0.39) | LGALS8ALDH1A1HIF1AMGAMSI | |
| SCHEMBL15267646 | 0.88 | LGALS8 (0.39) | LGALS8ALDH1A1HIF1AMGAMSI | |
| SCHEMBL23723836 | 0.88 | LGALS8 (0.43) | LGALS8ALDH1A1HIF1AGAAL3MBTL1 | |
| SCHEMBL13482776 | 0.88 | LGALS8 (0.43) | LGALS8ALDH1A1HIF1AGAAL3MBTL1 | |
| SCHEMBL14864297 | 0.88 | LGALS8 (0.43) | LGALS8ALDH1A1HIF1AGAAL3MBTL1 | |
| SCHEMBL18723048 | 0.88 | LGALS8 (0.43) | LGALS8ALDH1A1HIF1AGAAL3MBTL1 | |
| SCHEMBL20033536 | 0.88 | LGALS8 (0.43) | LGALS8ALDH1A1HIF1AGAAL3MBTL1 | |
| SCHEMBL16504207 | 0.88 | LGALS8 (0.43) | LGALS8ALDH1A1HIF1AGAAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2036917-B1 | NOVEL AMINOGLYCOSIDE ANTIBIOTIC | MEIJI SEIKA PHARMA CO LTD (JP) | 2015-10-07 | — | — | EP | disclosed |
| US-20120165283-A1 | NOVEL AMINOGLYCOSIDE ANTIBIOTICS | KOBAYASHI YOSHIHIKO (JP) | 2012-06-28 | — | — | US | disclosed |
| US-8148504-B2 | Aminoglycoside antibiotics | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2012-04-03 | — | — | US | disclosed |
| US-20090186841-A1 | Novel aminoglycoside antibiotics | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2009-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165283-A1 | NOVEL AMINOGLYCOSIDE ANTIBIOTICS | ATP6V1B1, REN, NRDC | LGALS8 1932/4885ALDH1A1 819/4885HIF1A 407/4885 |
| US-20090186841-A1 | Novel aminoglycoside antibiotics | ATP6V1B1, REN, NRDC | LGALS8 1932/4885ALDH1A1 819/4885HIF1A 407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.